GLUE
Monte Rosa Therapeutics Inc
NASDAQ: GLUE · HEALTHCARE · BIOTECHNOLOGY
$20.39
+5.37% today
Updated 2026-05-06
Market cap
$1.50B
P/E ratio
—
P/S ratio
12.16x
EPS (TTM)
$-0.46
Dividend yield
—
52W range
$4 – $26
Volume
1.1M
Monte Rosa Therapeutics Inc (GLUE) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | $11.09M | $49.38M | $366.33M | $342.39M | $303.75M | $438.73M |
| Cash & equivalents | $6.00M | $41.70M | $346.07M | $54.91M | $128.10M | $224.25M |
| Current assets | $9.76M | $43.59M | $348.67M | $275.89M | $236.21M | $377.44M |
| Total liabilities | $23.24M | $98.11M | $18.81M | $70.98M | $124.50M | $215.80M |
| Current liabilities | $4.29M | $29.27M | $16.64M | $25.57M | $46.59M | $156.95M |
| Long-term debt | — | — | — | — | — | — |
| Shareholder equity | $-12.15M | $-48.73M | $347.51M | $271.41M | $179.25M | $222.94M |
| Retained earnings | $-12.20M | $-48.08M | $-122.03M | $-230.54M | $-365.89M | $-438.59M |
| Accounts receivable | $51000.00 | $79000.00 | — | $7.66M | $505000.00 | $173000.00 |
| Inventory | — | — | — | $960000.00 | — | — |
| Goodwill | — | — | — | — | — | — |